Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There is a paucity of data on tapering and withdrawing therapy in psoriatic arthritis but advances in treatment and outcome measures suggest it is now time to be looking more closely at this. Several highly effective therapies are available providing the opportunity to achieve low disease activity. However, these therapies are associated with a marked increase in direct costs and patients are exposed to potentially life threatening adverse events. In addition to effective therapies the science of outcome assessment means that there are now suitable validated criteria for low disease activity which will allow both treat-to-target and a suitable measure of continuing low disease. Given these conditions, suitably designed randomized controlled trials of treatment withdrawal are now needed. Such studies will allow us to determine disease characteristics predictive of flare upon treatment withdrawal. In this way identifying which patients can successfully stop therapy will allow a more personalized approach to treatment decisions in PsA and will minimise risks and costs associated with ongoing therapy.


Journal article


Clin exp rheumatol

Publication Date





S51 - S53


Anti-Inflammatory Agents, Arthritis, Psoriatic, Biological Products, Cost-Benefit Analysis, Drug Administration Schedule, Drug Costs, Drug Therapy, Combination, Humans, Patient Selection, Recurrence, Remission Induction, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha